The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).
Task-sharing mental health care with non-specialist providers benefits adults with psychologic distress after experiencing violence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results